Sellekstaurin

希列克托灵

Report date: 2025/05/20 20:00:09
NME

Base Information

Drug NameSellekstaurin
Drug Alias NameMS-553
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein kinase C beta inhibitors
TargetsProtein kinase C beta
Therapy Area/IndicationsDiabetic macular oedemaDiabetes Mellitus, Type 1Lupus Erythematosus, Systemic +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaHong KongMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPfizer Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesMingsight Pharmaceuticals IncMingsight PharmaceuticalsShenzhen MingSight Relin Pharmaceuticals Co Ltd
Inactive CompaniesMingsight Pharmaceuticals Pty Ltd
Active IndicationsDiabetic macular oedemaDiabetes Mellitus, Type 1Macular Edema +[6] 
Inactive IndicationsLupus Erythematosus, SystemicArthritis, RheumatoidLymphoma, Mantle-Cell +[8] 

Other Information

ATC CodeN/A
Related LinksN/A